// App-Quantinova.ai

1583 : Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial

Researchers

Presenter

  • Lindsay Helget

Principal Investigators

  • James O'Dell

  • Jeff Newcomb

  • Maria Androsenko

  • Mary Brophy

  • Anne Davis-Karim

  • Bryant England

  • Ryan Ferguson

  • Michael Pillinger

  • Tuhina Neogi

  • Paul Palevsky

  • Hongsheng Wu

  • Ted Mikuls

Medical Centers

  • University of Nebraska Medical Center, Omaha, NE

  • VA Boston Cooperative Studies Program Coordinating Center, Boston, MA

  • VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM

  • Icahn School of Medicine, New York, NY

  • Tufts University School of Medicine, Boston, MA

  • University of Pittsburgh, School of Medicine, Pittsburgh, PA

  • Division of Radiology, University of Nebraska Medical Center, Omaha, NE

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Gout

Biomarkers

  • N/A

Drug/Treatment

  • Allopurinol

  • Febuxostat

  • Adenuric

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Non Inferiority

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved